iVeena Delivery Systems, Inc. (iVeena) is an independently owned, preclinical stage biopharmaceutical organization concentrating on broadening its platform technology for non-surgical, drug-related corneal flattening to create products that cater to unmet healthcare needs in the field of ophthalmology. The primary focus of the company is on IVMED-80, an innovative therapy for keratoconus. Additionally, iVeena is in the process of developing IVMED-85 and IVMED-95 for addressing pediatric high myopia and adult low myopia respectively.